BAX Jan 2024 70.000 call
| Previous close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 70.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.2500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 112 |
Simply Wall St.Here's Why We're Wary Of Buying Baxter International's (NYSE:BAX) For Its Upcoming Dividend
Baxter International Inc. ( NYSE:BAX ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one...
- Business Wire
Baxter to Present at Jefferies Healthcare Conference
DEERFIELD, Ill., May 24, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023. José (Joe) Almeida, Baxter’s chairman, president and chief executive officer, is scheduled to present at 10:00 a.m. Eastern Time.
- Simply Wall St.
Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Baxter International Inc. ( NYSE:BAX ) will pay a dividend of $0.29 on the 3rd of July. Based on this payment, the...
- Business Wire
Baxter Announces CFO Transition
DEERFIELD, Ill., May 09, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Jay Saccaro. Mr. Saccaro will leave Baxter at the end of May after 21 cumulative years with the company, including the past eight as CFO, to join a company in the healthcare industry.
Business WireBaxter Names Chris Toth CEO of Proposed Kidney Care Spinoff
DEERFIELD, Ill., May 05, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has selected Chris Toth to be chief executive officer (CEO) of the company’s planned spinoff of its Renal Care and Acute Therapies businesses. Until the spinoff, which remains subject to satisfaction of customary conditions and is currently expected to occur by July 2024 or earlier, Mr. Toth will serve as executive vice president and group president, Kidney Care, and report to Baxter
- Simply Wall St.
Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
The board of Baxter International Inc. ( NYSE:BAX ) has announced that it will pay a dividend on the 3rd of July, with...
ZacksBAX vs. SYK: Which Stock Should Value Investors Buy Now?
BAX vs. SYK: Which Stock Is the Better Value Option?
- Business Wire
Baxter Declares Quarterly Dividend
DEERFIELD, Ill., May 01, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on July 3, 2023, to shareholders of record as of June 2, 2023. The indicated annual dividend rate is $1.16 per share of common stock.
ZacksEnsign Group (ENSG) Beats on Q1 Earnings, Hikes '23 EPS View
Ensign Group's (ENSG) first-quarter results benefit from growing skilled services revenues. Management estimates EPS of $4.64-$4.77 for this year, higher than the earlier mentioned $4.60-$4.74.
ZacksBaxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View
Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
ZacksBaxter International (BAX) Q1 Earnings and Revenues Top Estimates
Baxter (BAX) delivered earnings and revenue surprises of 22.92% and 1.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Baxter Reports First-Quarter 2023 Results
DEERFIELD, Ill., April 27, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
ZacksMedical Device Stocks' Q1 Earnings on Apr 27: WST, DXCM, BAX
Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.
ZacksAre Investors Undervaluing Baxter International (BAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksBaxter (BAX) to Post Q1 Earnings: What's in the Offing?
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
- Business Wire
Baxter to Present at BofA Securities 2023 Health Care Conference
DEERFIELD, Ill., April 19, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
ZacksBaxter's (BAX) New Premix Drug Now Available in the U.S.
Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.
- Simply Wall St.
Baxter International (NYSE:BAX) shareholders are up 5.8% this past week, but still in the red over the last three years
Baxter International Inc. ( NYSE:BAX ) shareholders should be happy to see the share price up 11% in the last month...
- Business Wire
Baxter to Host First-Quarter 2023 Financial Results Conference Call for Investors
DEERFIELD, Ill., April 06, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/WhpPxesO to pre-register for the call and receive the call information.
- Business Wire
Baxter Launches Zosyn Premix in US
DEERFIELD, Ill., April 04, 2023--Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers. Please see Indications, Important Risk Information and link to full Prescribing Information below.
Business WireBaxter Showcases Surgical Innovations at AORN Global Surgical Conference and Expo 2023
DEERFIELD, Ill., April 03, 2023--Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023. These innovations include the launch of the new Baxter Patient Warming system, the unveiling of the Helux Pro Connected Surgical Light, and the launch of Floseal + Recothr
Business WireBaxter to Host Annual Meeting of Stockholders in Virtual Format
DEERFIELD, Ill., March 29, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2023 Annual Meeting) in a virtual format on Tuesday, May 2, 2023 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the meeting. Online access to the meeting will begin at 8:30 a.m., Central Time. Stockholders will not be able to attend the meeting in person. If you plan to attend the virtual meeting, please check https://investor.ba
Motley FoolIs It Time to Buy the S&P 500's 4 Worst-Performing Stocks of 2023?
After declining 19% in 2022, the S&P 500 has risen about 4% this year as investors grew accustomed to inflation, rising interest rates, and other macro headwinds. Let's see if the four worst-performing S&P 500 components so far in 2023 -- Lumen Technologies (NYSE: LUMN), Moderna (NASDAQ: MRNA), Baxter International (NYSE: BAX) and Pfizer (NYSE: PFE) -- are actually contrarian buys.
- Simply Wall St.
Baxter International Inc. (NYSE:BAX) is largely controlled by institutional shareholders who own 88% of the company
Key Insights Institutions' substantial holdings in Baxter International implies that they have significant influence...
- Simply Wall St.
Baxter International Full Year 2022 Earnings: EPS Misses Expectations
Baxter International ( NYSE:BAX ) Full Year 2022 Results Key Financial Results Revenue: US$15.1b (up 18% from FY 2021...